Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
XWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive Officer
Details : XWPharma expects to use proceeds to advance clinical development of the company’s lead investigational programs: XW10172, a GABAB receptor agonist intended for the treatment of sleep disorders in narcolepsy, Parkinson’s disease and other neurodegener...
Brand Name : XW10172
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 17, 2020
LOOKING FOR A SUPPLIER?